| General Information | |
|---|---|
| ZINC ID | ZINC000040973972 |
| Molecular Weight (Da) | 492 |
| SMILES | CCc1c(C2=NC(=S)C(C)(C)N2C)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1 |
| Molecular Formula | C23Cl3N4S1 |
| Action | Inverse Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 134.377 |
| HBA | 2 |
| HBD | 0 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 31 |
| LogP | 8.261 |
| Activity (Ki) in nM | 5.1286 |
| Polar Surface Area (PSA) | 65.51 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.191 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 17 |
| Fraction csp3 | 0.26 |
| Ilogp | 4.34 |
| Xlogp3 | 6.88 |
| Wlogp | 6.1 |
| Mlogp | 5.64 |
| Silicos-it log p | 8.04 |
| Consensus log p | 6.2 |
| Esol log s | -7.37 |
| Esol solubility (mg/ml) | 0.0000212 |
| Esol solubility (mol/l) | 4.31E-08 |
| Esol class | Poorly sol |
| Ali log s | -8.07 |
| Ali solubility (mg/ml) | 0.00000422 |
| Ali solubility (mol/l) | 8.58E-09 |
| Ali class | Poorly sol |
| Silicos-it logsw | -9.36 |
| Silicos-it solubility (mg/ml) | 0.00000021 |
| Silicos-it solubility (mol/l) | 4.40E-10 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.42 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 3 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 1 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.8 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -7.033 |
| Logd | 5.078 |
| Logp | 6.175 |
| F (20%) | 0.002 |
| F (30%) | 0.015 |
| Mdck | - |
| Ppb | 97.04% |
| Vdss | 1.817 |
| Fu | 2.49% |
| Cyp1a2-inh | 0.262 |
| Cyp1a2-sub | 0.935 |
| Cyp2c19-inh | 0.917 |
| Cyp2c19-sub | 0.906 |
| Cl | 5.059 |
| T12 | 0.058 |
| H-ht | 0.137 |
| Dili | 0.968 |
| Roa | 0.135 |
| Fdamdd | 0.751 |
| Skinsen | 0.025 |
| Ec | 0.003 |
| Ei | 0.009 |
| Respiratory | 0.665 |
| Bcf | 3.587 |
| Igc50 | 5.369 |
| Lc50 | 7.493 |
| Lc50dm | 5.533 |
| Nr-ar | 0.001 |
| Nr-ar-lbd | 0.015 |
| Nr-ahr | 0.348 |
| Nr-aromatase | 0.978 |
| Nr-er | 0.883 |
| Nr-er-lbd | 0.688 |
| Nr-ppar-gamma | 0.826 |
| Sr-are | 0.904 |
| Sr-atad5 | 0.018 |
| Sr-hse | 0.861 |
| Sr-mmp | 0.973 |
| Sr-p53 | 0.963 |
| Vol | 453.903 |
| Dense | 1.08 |
| Flex | 0.174 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 1 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 3 |
| Qed | 0.374 |
| Synth | 2.981 |
| Fsp3 | 0.261 |
| Mce-18 | 55.862 |
| Natural product-likeness | -0.951 |
| Alarm nmr | 2 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |